| NIH - National Institute of Neurological Disorders and Stroke | |
|---|---|
| NINDS Logo | |
| Location | Bethesda, MD, USA |
| Type | Government Research Institute |
| Founded | 1950 |
| Annual Budget | ~$2.4 billion (FY2024) |
| Website | https://www.ninds.nih.gov/ |
| Focus Areas | [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), Stroke, [FTD](/diseases/frontotemporal-dementia) |
| Director | Dr. Walter J. Koroshetz |
The National Institute of Neurological Disorders and Stroke (NINDS) is one of 27 institutes and centers that comprise the National Institutes of Health (NIH). Established in 1950, NINDS is the primary federal agency supporting research on the brain and nervous system, with an annual budget of approximately $2.4 billion[1].
NINDS plays a pivotal role in advancing understanding, treatment, and prevention of neurological disorders, including neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD). The institute supports research through both intramural (internal) and extramural (external grant funding) programs, making it the largest funder of neuroscience research in the United States[@koroshartz2020].
As part of the NIH's broader Accelerating Medicines Partnership (AMP), NINDS leads significant initiatives targeting neurodegenerative disease drug discovery and biomarker development[2]. The institute's research portfolio spans basic science, translational research, and clinical trials, positioning it at the forefront of efforts to develop disease-modifying therapies for conditions that currently lack effective treatments.
NINDS was established in 1950 as the National Institute of Neurological Diseases and Blindness, combining research on neurological disorders with vision research. In 1956, the name was changed to the National Institute of Neurological Diseases and Stroke, and later shortened to the National Institute of Neurological Disorders and Stroke. Vision research was transferred to the National Eye Institute in 1968.
Over the decades, NINDS has evolved from a small institute focused primarily on basic neuroscience to a comprehensive research agency addressing the full spectrum of neurological disorders. The institute's mission has expanded to include:
NINDS's current strategic plan for neurodegenerative disease research emphasizes[3]:
NINDS supports a comprehensive portfolio of Alzheimer's disease research[4][5]:
Basic Research:
Translational Research:
Clinical Research:
NINDS is a key partner in the AMP-AD initiative, a public-private partnership that aims to identify and validate novel therapeutic targets[2:1]:
NINDS supports extensive Parkinson's disease research[6]:
Key Programs:
Research Focus Areas:
NINDS supports research on ALS and FTD, which share overlapping mechanisms[8]:
Research Portfolio:
Clinical Trials:
NINDS is a major funder of stroke research[9]:
Program Areas:
Networks:
NINDS provides funding through various mechanisms:
| Mechanism | Purpose | Typical Award Size |
|---|---|---|
| R01 | Research Project Grant | $250-500K/year |
| R21 | Exploratory/Developmental | $100-200K/year |
| R35 | Research Program Award | $1-2M/year |
| U01 | Cooperative Agreement | Varies |
| P50 | Specialized Center | $2-5M/year |
| K99/R00 | Career Transition Award | $250K+ |
| F31/F32 | Fellowships | $30-50K/year |
Udall Centers of Excellence
The NINDS Udall Centers program funds comprehensive Parkinson's disease research centers across the United States. Each center brings together basic, translational, and clinical researchers to accelerate progress toward new treatments.
NINDS Alzheimer Disease Research Centers
These centers conduct innovative research on Alzheimer's disease and related disorders, with emphasis on early detection, treatment, and prevention.
Clinical Trials Infrastructure
NINDS supports clinical trial infrastructure through[10]:
NINDS supports training through multiple mechanisms[11]:
Predoctoral Training:
Postdoctoral Training:
Clinical Training:
NINDS supports career progression through:
NINDS participates in AMP programs for:
These partnerships bring together NIH, pharmaceutical companies, and nonprofit organizations to accelerate drug target identification and validation.
NINDS coordinates NIH StrokeNet, a national network conducting multi-site clinical trials for stroke prevention, treatment, and recovery[9:1].
NINDS collaborates with international partners:
NINDS supports research on rare neurological diseases[@siegal2022]:
NINDS conducts internal (intramural) research at the NIH campus in Bethesda:
NINDS supports several major data resources:
| Resource | Description | Access |
|---|---|---|
| AMP-AD Knowledge Portal | Multi-omics data | Open |
| PPMI Data | Parkinson's biomarker data | Open |
| NIH Blueprint | Neuroscience tools | Open |
| NINDS Biofluid Bank | Biospecimens | Request |
NINDS maintains repositories of biospecimens for research:
NINDS-funded research has contributed to major advances:
NINDS's future research directions include:
NIH - National Institute of Neurological Disorders and Stroke official website. 2026. ↩︎
Collins FS et al. NIH Accelerating Medicines Partnership for AD. 2017. ↩︎ ↩︎
Koroshetz WJ et al. NINDS strategic plan for neurodegenerative disease. 2020. ↩︎
Parker WE et al. NINDS Alzheimer disease research programs. Ann Neurol. 2020. ↩︎
Scheltens P et al. Alzheimer's disease. Lancet. 2016. ↩︎
Kalia LV, Lang AE. Parkinson's disease. Lancet. 2021. ↩︎
Marek K et al. Parkinson Progression Marker Initiative (PPMI). 2019. ↩︎
Taylor JP et al. ALS and FTD research. 2019. ↩︎
Singh J et al. NINDS stroke research programs. 2016. ↩︎ ↩︎
Sims JR et al. NINDS clinical trials infrastructure. 2019. ↩︎
Holder J et al. NINDS training programs in neurology. 2020. ↩︎